2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes

San Francisco, CA US
October 7, 2023 to October 8, 2023

The 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations across common malignancies.

Expert faculty will discuss and analyze the latest scientific findings and practice-changing advances in precision oncology, including the key abstracts relevant to precision oncology presented at the 2023 ASCO Annual Meeting in June 2023.

This conference will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:

  • Integrating different platforms available for testing of actionable molecular alterations for identification of targeted therapy options.
  • Current and evolving paradigms in precision oncology approach for management of common malignancies.
  • Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.



888 Howard Street
San Francisco, CA 94103
United States

Target Audience


  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients


Learning Objectives

Upon successful completion of this educational activity on precision oncology, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
  • Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
  • Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.
Course summary
Course opens: 
Course expires: 
Event starts: 
10/07/2023 - 3:00pm PDT
Event ends: 
10/08/2023 - 4:30pm PDT

Preliminary Agenda:



1:00 PM to 2:00 PM           Registration/Exhibits

2:00 PM to 3:30 PM           Abstract Session 1 

3:45 PM to 4:00 PM           Welcome - note from the conference chair 

4:00 PM to 5:15 PM          Session 1: Methods in Precision Oncology 
Moderator: TBA

4:00 PM to 4:15 PM           Next-generation sequencing for identification of molecular targets - TBA
4:15 PM to 4:30 PM           Beyond sequencing – methods in identifying tumor biomarkers for targeted therapies - TBA
4:30 PM to 4:45 PM           Germline genetic testing for cancer prevention and treatment - TBA
4:45 PM to 5:00 PM           Clinical utility of circulating tumor DNA in cancer treatment - TBA
5:00 PM to 5:15 PM           Panel discussion - TBA

5:20 PM to 6:05 PM           Session 2: Somatic and Germline Testing: Real-World Challenges 
Moderator: TBA

5:20 PM to 5:35 PM           Challenges and solutions with somatic genetic testing: what is needed - TBA
5:35 PM to 5:50 PM           Challenges and solutions with germline testing - TBA
5:50 PM to 6:05 PM           Panel discussion - TBA

6:05 PM to 6:30 PM           Break & Exhibits

6:15 PM to 8:15 PM           Abstract Session 2 

6:30 PM to 8:30 PM           Binaytara Foundation's Reception Dinner




7:00 AM to 7:30 AM           Breakfast and registration

7:30 AM to 8:45 AM           Session 3: Precision Oncology in Breast and Ovarian Cancer
Moderator: TBA  

7:30 AM to 7:45 AM           Precision oncology in metastatic breast cancer - TBA
7:45 AM to 8:00 AM           Non-metastatic breast cancer - TBA
8:00 AM to 8:15 AM           Key concepts on precision in gynecological malignancies - TBA 
8:15 AM to 8:45 AM           Panel discussion - TBA

8:50 AM to 10:05 AM           Session 4: Precision Oncology in Lung Cancer
Moderator: TBA

8:50 AM to 9:05 AM           Metastatic lung cancer - TBA        
9:05 AM to 9:20 AM           Adjuvant treatment of lung cancer - TBA
9:20 AM to 10:05 AM         Panel discussion - TBA

10:05 AM to 10:20 AM           Break

10:20 AM to 11:20 AM           Session 5: Precision Oncology in GI Malignancies
Moderator: TBA

10:20 AM to 10:35 AM           Precision Oncology in Colon cancer - TBA
10:35 AM to 10:50 AM           Hepatobiliary and pancreatic malignancies - TBA
10:50 AM to 11:20 AM           Panel-based discussion - TBA

11:25 AM to 12:25 PM           Session 6: Precision Oncology in Prostate Cancer
Moderator: TBA

11:25 AM to 11:40 AM           Precision oncology in metastatic prostate cancer - TBA
11:40 AM to 11:55 AM           Precision oncology in metastatic bladder cancer - TBA
11:55 AM to 12:25 PM           Panel-based discussion - TBA

12:25 PM to 1:15 PM           Lunch & Exhibits

1:15 PM to 2:15 PM           Session 7: Precision Oncology in Hematological Malignancies
Moderator: TBA

1:15 PM to 1:30 PM           Precision oncology in acute leukemias - TBA
1:30 PM to 1:45 PM           Precision oncology in multiple myeloma - TBA
1:45 PM to 2:15 PM           Panel discussion – TBA

2:20 PM to 3:20 PM           Session 8: Precision Medicine: Perspectives from Molecular Pathologists
Moderator: TBA

2:20 PM to 2:25 PM           Introduction 
2:25 PM to 2:40 PM           Pre-Analytical Variables and Precision Oncology: How we can improve our Patient Management - TBA
2:40 PM to 2:55 PM           Critical Role of Molecular Pathologist in Precision Oncology - TBA
2:55 PM to 3:20 PM           Panel discussion - TBA

3:20 PM to 3:30 PM           Break/Exhibits

3:30 PM to 4:30 PM           Session 9: Implementation Science in Precision Oncology
Moderator: TBA

3:30 PM to 3:45 PM           Disparities in precision oncology and improving access to evidence-based testing for targeted therapies - TBA
3:45 PM to 4:00 PM           Strategies for clinical implementation of precision oncology - TBA
4:00 PM to 4:30 PM           Panel discussion -TBA

4:30 PM           Concluding remarks 

888 Howard Street
San Francisco, CA 94103
United States
+1 (415) 616-6627


Accreditation information coming soon.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information



Please login or register to take this course.


Physicians (non-industry) - $350

Non-physician HCP (non-industry) - $250

Industry representatives - $1250

Fellow or resident - $200


If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Cancellation Policy

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.